Pharmacodynamic and pharmacokinetic study of ultra-rapid Lispro (URLi) versus humalog in patients with type 2 diabetes: A randomised, double-blind, six-period crossover study
Latest Information Update: 17 Oct 2018
At a glance
- Drugs Insulin lispro (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Pharmacokinetics
- 05 Oct 2018 Results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 23 Jul 2018 New trial record
- 26 Jun 2018 Results presented at the 78th Annual Scientific Sessions of the American Diabetes Association